The chronic kidney disease market size has grown strongly in recent years. It will grow from $65.74 billion in 2023 to $70.2 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be attributed to several factors, including the prevalence of the hypertension and diabetes epidemic, an aging population, unhealthy lifestyles, disparities in healthcare access, and advancements in medical technologies. These factors collectively contributed to the increased incidence and awareness of chronic kidney disease during that period.
The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $88.26 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period can be attributed to a focused healthcare policy, the development of precision medicine, an increase in obesity rates, the growth of chronic diseases, and improvements in healthcare access. Key trends in the forecast period include campaigns promoting early screening, the integration of telemedicine and remote monitoring, programs empowering patients, initiatives for community-based care, and the integration of nutritional therapy. These trends collectively contribute to the evolving landscape of chronic kidney disease management and care.
The escalating prevalence of kidney disease is poised to drive the expansion of the chronic kidney disease (CKD) market. Kidney diseases encompass various conditions that affect the kidneys' function and structure, often necessitating medication to manage symptoms, control blood pressure, and minimize protein loss. As per data from the Centers for Disease Control and Prevention in July 2022, approximately 15% or 37 million individuals in the US grapple with kidney disease, underscoring the surge in its prevalence. Consequently, this mounting prevalence is a key driver propelling the growth trajectory of the chronic kidney disease market.
The burgeoning aging population is anticipated to contribute significantly to the chronic kidney disease market's expansion. The term 'aging population' denotes a demographic trend marked by a higher proportion of elderly individuals within a society or populace. This demographic shift is closely associated with an elevated reliance on chronic kidney disease (CKD) management due to the rising incidence of kidney-related issues among the elderly. With age, the risk of kidney ailments, including CKD, tends to escalate. Notably, the World Health Organization's October 2022 report highlights a rapid growth projection for the global population aged 60 years and older, expected to double by 2050, reaching an estimated 2.1 billion individuals. Hence, the increasing aging demographic is a significant factor propelling the chronic kidney disease market's growth trajectory.
Product innovation stands out as a pivotal trend gaining momentum in the chronic kidney disease market. Companies navigating this sector are dedicating efforts toward developing innovative products to fortify their market presence. For example, Bayer, a Germany-based biotechnology and pharmaceutical entity, unveiled Kerendia (finerenone) in August 2022. This groundbreaking medicine, categorized as a non-steroidal, selective mineralocorticoid receptor antagonist, offers a novel approach to decelerate chronic kidney disease progression among diabetic patients. Its distinctive mechanism involves the blocking of mineralocorticoid receptor (MR) overactivation, thereby addressing factors contributing to CKD progression and associated cardiovascular damage, setting it apart from existing treatments.
Major players in the chronic kidney disease market are engaging in strategic partnerships to explore the safety and efficacy of an enhanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. These strategic partnerships involve collaborations where companies harness each other's strengths and resources to achieve mutual benefits. As an illustration, in June 2023, AWAK Technologies Pte Ltd., a Singapore-based medical technology firm, forged a partnership with Singapore General Hospital Pte Ltd. (SGH), an academic health science center and hospital entity in Singapore. This collaboration aims to revolutionize kidney disease diagnosis, treatment, and management by spearheading the development and evaluation of AWAK PD, a wearable and ultra-portable peritoneal dialysis (PD) system. This innovative system allows end-stage kidney disease patients the flexibility to undergo dialysis at home and while on the move, thereby enhancing their quality of life and treatment convenience.
In January 2023, the US-based biopharmaceutical company AstraZeneca Pharmaceuticals LP successfully acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca aims to enrich its cardiorenal pipeline by incorporating CinCor's candidate medicine, baxdrostat (CIN-107). Baxdrostat is an aldosterone synthase inhibitor (ASI) designed for blood pressure control in the treatment of resistant hypertension. CinCor Pharma Inc., based in the US, is a clinical-stage biopharmaceutical company specializing in the development of products for the treatment of resistant and uncontrolled hypertension, as well as chronic kidney disease.
Major companies operating in the chronic kidney disease market report are Pfizer Inc., Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp.
North America was the largest region in the chronic kidney disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Key diagnostic tests for chronic kidney disease include blood tests, urine tests, imaging tests, and kidney biopsy. Blood tests involve the examination of a blood sample for medical evaluation. Treatment modalities encompass drugs, dialysis, kidney transplants, ACE inhibitors, and other interventions. These drugs can be administered through oral, intravenous, and subcutaneous routes, catering to various end-users such as hospitals, clinics, ambulatory surgery centers (ASCS), dialysis centers, and others.
The chronic kidney disease market research report is one of a series of new reports that provides chronic kidney disease market statistics, including the chronic kidney disease industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed chronic kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. This chronic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The chronic kidney disease market size is expected to see strong growth in the next few years. It will grow to $88.26 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth in the forecast period can be attributed to a focused healthcare policy, the development of precision medicine, an increase in obesity rates, the growth of chronic diseases, and improvements in healthcare access. Key trends in the forecast period include campaigns promoting early screening, the integration of telemedicine and remote monitoring, programs empowering patients, initiatives for community-based care, and the integration of nutritional therapy. These trends collectively contribute to the evolving landscape of chronic kidney disease management and care.
The escalating prevalence of kidney disease is poised to drive the expansion of the chronic kidney disease (CKD) market. Kidney diseases encompass various conditions that affect the kidneys' function and structure, often necessitating medication to manage symptoms, control blood pressure, and minimize protein loss. As per data from the Centers for Disease Control and Prevention in July 2022, approximately 15% or 37 million individuals in the US grapple with kidney disease, underscoring the surge in its prevalence. Consequently, this mounting prevalence is a key driver propelling the growth trajectory of the chronic kidney disease market.
The burgeoning aging population is anticipated to contribute significantly to the chronic kidney disease market's expansion. The term 'aging population' denotes a demographic trend marked by a higher proportion of elderly individuals within a society or populace. This demographic shift is closely associated with an elevated reliance on chronic kidney disease (CKD) management due to the rising incidence of kidney-related issues among the elderly. With age, the risk of kidney ailments, including CKD, tends to escalate. Notably, the World Health Organization's October 2022 report highlights a rapid growth projection for the global population aged 60 years and older, expected to double by 2050, reaching an estimated 2.1 billion individuals. Hence, the increasing aging demographic is a significant factor propelling the chronic kidney disease market's growth trajectory.
Product innovation stands out as a pivotal trend gaining momentum in the chronic kidney disease market. Companies navigating this sector are dedicating efforts toward developing innovative products to fortify their market presence. For example, Bayer, a Germany-based biotechnology and pharmaceutical entity, unveiled Kerendia (finerenone) in August 2022. This groundbreaking medicine, categorized as a non-steroidal, selective mineralocorticoid receptor antagonist, offers a novel approach to decelerate chronic kidney disease progression among diabetic patients. Its distinctive mechanism involves the blocking of mineralocorticoid receptor (MR) overactivation, thereby addressing factors contributing to CKD progression and associated cardiovascular damage, setting it apart from existing treatments.
Major players in the chronic kidney disease market are engaging in strategic partnerships to explore the safety and efficacy of an enhanced Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. These strategic partnerships involve collaborations where companies harness each other's strengths and resources to achieve mutual benefits. As an illustration, in June 2023, AWAK Technologies Pte Ltd., a Singapore-based medical technology firm, forged a partnership with Singapore General Hospital Pte Ltd. (SGH), an academic health science center and hospital entity in Singapore. This collaboration aims to revolutionize kidney disease diagnosis, treatment, and management by spearheading the development and evaluation of AWAK PD, a wearable and ultra-portable peritoneal dialysis (PD) system. This innovative system allows end-stage kidney disease patients the flexibility to undergo dialysis at home and while on the move, thereby enhancing their quality of life and treatment convenience.
In January 2023, the US-based biopharmaceutical company AstraZeneca Pharmaceuticals LP successfully acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca aims to enrich its cardiorenal pipeline by incorporating CinCor's candidate medicine, baxdrostat (CIN-107). Baxdrostat is an aldosterone synthase inhibitor (ASI) designed for blood pressure control in the treatment of resistant hypertension. CinCor Pharma Inc., based in the US, is a clinical-stage biopharmaceutical company specializing in the development of products for the treatment of resistant and uncontrolled hypertension, as well as chronic kidney disease.
Major companies operating in the chronic kidney disease market report are Pfizer Inc., Johnson and Johnson Services Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceuticals Ltd., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Novo Nordisk AS, Siemens Healthineers AG, AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Beckman Coulter Inc., Kissei Pharmaceutical Co. Ltd., Akebia Therapeutics Inc., Mission Therapeutics Ltd., Tricida Inc., Regulus Therapeutics Inc., Goldfinch Bio Co, Alio Inc., Monogram Health, Strive Health, Maze Therapeutics, ProKidney Corp.
North America was the largest region in the chronic kidney disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic kidney disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Key diagnostic tests for chronic kidney disease include blood tests, urine tests, imaging tests, and kidney biopsy. Blood tests involve the examination of a blood sample for medical evaluation. Treatment modalities encompass drugs, dialysis, kidney transplants, ACE inhibitors, and other interventions. These drugs can be administered through oral, intravenous, and subcutaneous routes, catering to various end-users such as hospitals, clinics, ambulatory surgery centers (ASCS), dialysis centers, and others.
The chronic kidney disease market research report is one of a series of new reports that provides chronic kidney disease market statistics, including the chronic kidney disease industry global market size, regional shares, competitors with a chronic kidney disease market share, detailed chronic kidney disease market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic kidney disease industry. This chronic kidney disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chronic kidney disease market consists of revenues earned by entities by providing peritoneal dialysis, in-center hemodialysis, and home hemodialysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic kidney disease market also includes sales such as captopril, enalapril, finerenone, and fosinopril used during the treatment procedure. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Chronic Kidney Disease Market Characteristics3. Chronic Kidney Disease Market Trends and Strategies32. Global Chronic Kidney Disease Market Competitive Benchmarking33. Global Chronic Kidney Disease Market Competitive Dashboard34. Key Mergers and Acquisitions in the Chronic Kidney Disease Market
4. Chronic Kidney Disease Market - Macro Economic Scenario
5. Global Chronic Kidney Disease Market Size and Growth
6. Chronic Kidney Disease Market Segmentation
7. Chronic Kidney Disease Market Regional and Country Analysis
8. Asia-Pacific Chronic Kidney Disease Market
9. China Chronic Kidney Disease Market
10. India Chronic Kidney Disease Market
11. Japan Chronic Kidney Disease Market
12. Australia Chronic Kidney Disease Market
13. Indonesia Chronic Kidney Disease Market
14. South Korea Chronic Kidney Disease Market
15. Western Europe Chronic Kidney Disease Market
16. UK Chronic Kidney Disease Market
17. Germany Chronic Kidney Disease Market
18. France Chronic Kidney Disease Market
19. Italy Chronic Kidney Disease Market
20. Spain Chronic Kidney Disease Market
21. Eastern Europe Chronic Kidney Disease Market
22. Russia Chronic Kidney Disease Market
23. North America Chronic Kidney Disease Market
24. USA Chronic Kidney Disease Market
25. Canada Chronic Kidney Disease Market
26. South America Chronic Kidney Disease Market
27. Brazil Chronic Kidney Disease Market
28. Middle East Chronic Kidney Disease Market
29. Africa Chronic Kidney Disease Market
30. Chronic Kidney Disease Market Competitive Landscape and Company Profiles
31. Chronic Kidney Disease Market Other Major and Innovative Companies
35. Chronic Kidney Disease Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Chronic Kidney Disease Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on chronic kidney disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for chronic kidney disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Diagnosis: Blood Test; Urine Test; Imaging Test; Kidney Biopsy
2) By Treatment: Drugs; Dialysis; Kidney Transplant; ACE Inhibitors; Blood Test; Other Treatments
3) By Route of Administration: Oral; Intravenous; Subcutaneous
4) By End-user: Hospital and Clinics; Ambulatory Surgery Centers (ASCs); Dialysis Centers; Other End-Users
Key Companies Mentioned: Pfizer Inc; Johnson and Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc
- Johnson and Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- AbbVie Inc.
- Bayer AG
- Novartis International AG
- Sanofi SA
- Bristol-Myers Squibb Company
- Abbott laboratories Inc.
- GlaxoSmithKline PLC
- Takeda Pharmaceuticals Ltd.
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Amgen Inc.
- Novo Nordisk AS
- Siemens Healthineers AG
- AstraZeneca Pharmaceuticals LP
- Teva Pharmaceutical Industries Ltd.
- Beckman Coulter Inc.
- Kissei Pharmaceutical Co. Ltd.
- Akebia Therapeutics Inc.
- Mission Therapeutics Ltd.
- Tricida Inc.
- Regulus Therapeutics Inc.
- Goldfinch Bio Co
- Alio Inc.
- Monogram Health
- Strive Health
- Maze Therapeutics
- ProKidney Corp
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 70.2 Billion |
| Forecasted Market Value ( USD | $ 88.26 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
